• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

    12/3/24 9:00:00 AM ET
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $HYPR alert in real time by email

    Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond.

    Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster the capability of Hyperfine to drive Swoop® system commercial adoption in hospital inpatient and outpatient settings and expand to neurology office settings.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203244752/en/

    The Swoop® Portable MR Imaging® System (Photo: Business Wire)

    The Swoop® Portable MR Imaging® System (Photo: Business Wire)

    Chi Nguyen will lead the company's office strategy, drawing on her extensive experience in developing markets for disruptive technologies. The new MRI standards issued by the Intersocietal Accreditation Commission (IAC) in November 2024 open the door for accredited neurology offices to secure CMS reimbursement for MRI scans using the Swoop® system. This milestone positions Hyperfine to expand into new sites of care, including neurology offices—representing nearly 2,400 potential locations in the U.S. alone. By bringing advanced MR brain imaging directly to these professional healthcare settings, Hyperfine will significantly enhance patient access and convenience by enabling MR brain imaging during routine clinic visits. To lay the foundation for this expansion, Ms. Nguyen will oversee an office pilot program in preparation for a full commercial rollout scheduled for mid-2025.

    Rafael Donnay will lead the company's hospital strategy, leveraging his expertise in commercialization, market development of new technologies, and health economics to position the Swoop® system as an essential tool in a range of hospital settings. With a focus on market expansion, the company is targeting over 9,600 potential sites of care in the U.S. alone, including 4,000 critical care units and 5,600 emergency departments. With a track record of successful commercialization of AI-powered point-of-care EEG and extensive experience in the neurovascular space, Mr. Donnay will focus on integrating the Swoop® system into hospital workflows to optimize patient care.

    Beyond the hospital and office business verticals, growth in 2025 will be driven by international expansion efforts, supported by the recent CE approval of the latest AI-powered Swoop® system software. This milestone positions Hyperfine for broader European commercial expansion of the Swoop® system, bringing cutting-edge brain imaging technology to new global markets.

    Maria Sainz, President and CEO of Hyperfine, commented, "The addition of Chi and Rafael to our leadership team is a pivotal step in our expansion and growth strategy. Their expertise in market development, commercialization of disruptive technologies, and health economics will be instrumental as we expand the Swoop® system's reach. With their leadership, Hyperfine is well-positioned to drive growth and transform care delivery in hospital and neurology office settings."

    For more information about the Swoop® Portable MR Imaging® system, please visit hyperfine.io.

    About Chi Nguyen

    Chi Nguyen is a seasoned medical device executive with over two decades of experience in strategy, marketing, and market development, specializing in the commercialization of disruptive medical technologies. She previously served as Vice President of Marketing at NeuroPace, Inc., where she successfully led market expansion efforts from early launch through IPO. Her earlier roles include Spinal Modulation, Acclarent/Johnson & Johnson, Guidant Corporation, and Bain & Company. Chi holds an MBA from Stanford Graduate School of Business and a BA from Yale University.

    About Rafael Donnay

    Rafael Donnay, with over twenty years of experience in medical technology, is driven by a passion to improve healthcare using innovative and disruptive technologies. He most recently served as Senior Vice President of Product and Reimbursement at CeriBell Inc., a leadership team member from Series A to IPO. Rafael's prior marketing leadership roles include Philips, Stryker Neurovascular, and Medtronic. He holds an MBA from The Wharton School, an MS from Stanford University, and a BS from Columbia University.

    About the Swoop® Portable MR Imaging® System

    The Swoop® Portable MR Imaging® system is U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. It is a portable, ultra-low-field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. The Swoop® system also has CE certification in the European Union and UKCA certification in the United Kingdom. The Swoop® system is commercially available in a select number of international markets.

    About Hyperfine, Inc.

    Hyperfine, Inc. (NASDAQ:HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit hyperfine.io.

    The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc.

    Forward-Looking Statements

    This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241203244752/en/

    Get the next $HYPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Q&A

    New
    • Who are the new executives appointed at Hyperfine, and what are their roles?

      Chi Nguyen has been appointed as the Vice President of Office Strategy and Partnerships at Hyperfine, focusing on expanding the Swoop® system into neurology office settings.

    • What is Rafael Donnay's focus as the new Vice President of Hospital Strategy at Hyperfine?

      Rafael Donnay will drive the hospital strategy to enhance the integration of the Swoop® system into hospital workflows, targeting critical care units and emergency departments to improve patient care.

    • What is the projected market for the Swoop® system in terms of potential hospital and office locations?

      The Swoop® system's expansion is expected to reach over 9,600 potential hospital care sites and nearly 2,400 neurology office locations in the U.S. by 2025.

    • What are Hyperfine's growth aspirations for 2025 and beyond?

      Hyperfine aims for significant growth in 2025, bolstered by international expansion efforts and the new MRI standards that enable reimbursement for MRI scans in accredited neurology offices.

    • What recent regulatory achievement supports Hyperfine's expansion into European markets?

      The most recent milestone is the CE approval of the Swoop® system, which will support Hyperfine's broader European commercial expansion.

    Recent Analyst Ratings for
    $HYPR

    DatePrice TargetRatingAnalyst
    8/11/2022$8.00 → $2.40Overweight → Equal Weight
    Wells Fargo
    5/31/2022$7.00Outperform
    Evercore ISI
    4/14/2022$8.00Overweight
    Wells Fargo
    More analyst ratings

    $HYPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hyperfine Inc.

      SC 13G - Hyperfine, Inc. (0001833769) (Subject)

      2/13/24 5:06:19 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      2/14/23 4:07:09 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by Hyperfine Inc. (Amendment)

      SC 13G/A - Hyperfine, Inc. (0001833769) (Subject)

      12/20/22 4:22:37 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine Enrolls Initial Patients in NEURO PMR Study to Evaluate Use of AI-Powered Portable MRI in Neurology Offices

      Real-world study will assess clinical utility and patient experience across diverse neurological conditions to support adoption of AI-powered portable MRI systems in the office setting. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system, first approved in 2021—today announced the enrollment of initial patients in the NEURO PMR (Neurological Evaluation in the Office with Portable MRI) study. The NEURO PMR study is the first multi-center, prospective observational study of its kind, comparing portable ultra-low-field MRI and

      4/15/25 4:00:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      GUILFORD, Conn., March 17, 2025 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced fourth quarter and full year 2024 financial results and provided a business update. "I am pleased with the many milestones we achieved in the fourth quarter of 2024. These set the stage well for us to execute on our expansion plan, drive accelerated growth across multiple sites of care globally and meaningfully reduce cash burn in 2025," said Maria Sainz, Chief Executive Officer and President of Hyperfine,

      3/17/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    SEC Filings

    See more
    • Hyperfine Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Hyperfine, Inc. (0001833769) (Filer)

      5/2/25 4:08:40 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEFA14A filed by Hyperfine Inc.

      DEFA14A - Hyperfine, Inc. (0001833769) (Filer)

      4/7/25 4:06:35 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Hyperfine Inc.

      DEF 14A - Hyperfine, Inc. (0001833769) (Filer)

      4/7/25 4:05:07 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Financials

    Live finance-specific insights

    See more
    • Hyperfine, Inc. to Announce First Quarter 2025 Financial Results on May 13, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the first quarter 2025 on Tuesday, May 13, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call. About the Swo

      4/29/25 4:28:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025

      Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced that it will report financial results for the fourth quarter and full year 2024 on Monday, March 17, 2025. Management will host a corresponding conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A live audio webcast and an archive of the recording will be available through the Investors page of Hyperfine, Inc.'s corporate website at https://investors.hyperfine.io/. Participants are encouraged to register more than 15 minutes before the start of the call

      3/4/25 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Reports Third Quarter 2024 Financial Results

      GUILFORD, Connecticut, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced third quarter 2024 financial results and provided a business update. "The Hyperfine team delivered yet another strong quarter of financial performance across revenue growth, gross margin expansion, and disciplined cash management while executing against several important priorities in our plans to expand into new sites of care and internationally," said Maria Sainz, Chief Executive Officer and President of Hy

      11/12/24 4:05:00 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Chief Operating Officer Teisseyre Thomas sold $3,497 worth of shares (3,238 units at $1.08), decreasing direct ownership by 4% to 84,989 units (SEC Form 4)

      4/A - Hyperfine, Inc. (0001833769) (Issuer)

      2/20/25 5:23:21 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas sold $3,884 worth of shares (3,237 units at $1.20), decreasing direct ownership by 4% to 84,990 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      2/18/25 7:03:33 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Chief Operating Officer Teisseyre Thomas sold $2,380 worth of shares (2,800 units at $0.85), decreasing direct ownership by 3% to 88,227 units (SEC Form 4)

      4 - Hyperfine, Inc. (0001833769) (Issuer)

      11/18/24 5:41:50 PM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hyperfine downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Hyperfine from Overweight to Equal Weight and set a new price target of $2.40 from $8.00 previously

      8/11/22 6:32:27 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Evercore ISI initiated coverage on Hyperfine with a new price target

      Evercore ISI initiated coverage of Hyperfine with a rating of Outperform and set a new price target of $7.00

      5/31/22 7:16:51 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Wells Fargo initiated coverage on Hyperfine with a new price target

      Wells Fargo initiated coverage of Hyperfine with a rating of Overweight and set a new price target of $8.00

      4/14/22 7:32:25 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $HYPR
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Hyperfine Announces Strategic Leadership Additions to Drive Growth in Key Business Verticals

      Two new executive roles position Hyperfine to drive the adoption of the Swoop® system in hospital settings and expand into the office setting, laying the foundation for significant growth in 2025 and beyond. Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced the appointment of Chi Nguyen as Vice President of Office Strategy and Partnerships and Rafael Donnay as Vice President of Hospital Strategy and Health Economics to provide leadership in key growth areas. These strategic leadership appointments bolster t

      12/3/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Hyperfine, Inc. Continues Global Market Expansion by Entering Into a Distribution Partnership with Radiosurgery Global, Ltd. to Bring the Swoop® System to India

      Strategic focus on India aims to make the Swoop® portable MR brain imaging system commercially available in a vast and underserved MRI market Hyperfine, Inc. (NASDAQ:HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced it has entered into a distribution agreement with Radiosurgery Global, Ltd. to develop the market in India. The distribution agreement also includes the countries of Malaysia, Indonesia, and Singapore through future expansion, offering Hyperfine, Inc. a significantly increased presence in Asia. The clinical value of the Swoop®

      5/28/24 9:00:00 AM ET
      $HYPR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care